On Monday, Shares of Enzon Pharmaceuticals Inc. (NASDAQ:ENZN), surged 17.36% to $1.42, after the company declared a special cash dividend for its investors. The biotechnology company will pay the special dividend on August 12, 2015 to its shareholders of record on July 21, 2015. One of the most impressive facts about Enzon Pharmaceuticals is its return on assets, which stands at 88.70%. The biotechnology company declared three new directors in its annual shareholder meeting held on June 30, 2015. The Piscataway, New Jersey based company offers licensing for a huge portfolio of drugs counting PegIntron for the treatment of chronic Hepatitis C, Macugen for macular degeneration associated with neovascular issues, Sylatron for melanoma, and CIMZIA for Crohn’s disease & rheumatoid arthritis.
Enzon Pharmaceuticals, Inc. engages in licensing drug products. Its marketed drug products comprise PegIntron for chronic hepatitis C; Sylatron for melanoma; Macugen for neovascular (wet) age-related macular degeneration; and CIMZIA for the treatment of rheumatoid arthritis and Crohn’s disease. The company was founded in 1981 and is headquartered in Piscataway, New Jersey.
Shares of PulteGroup, Inc. (NYSE:PHM), inclined 0.10% to $20.57, during its last trading session.
PulteGroup, declared that it will release its second quarter 2015 financial results before the market opens on Thursday, July 23, 2015. The Company will hold a conference call to talk about second quarter results that same day at 8:30 a.m. (ET).
PulteGroup, Inc., through its auxiliaries, engages in the homebuilding business; mortgage banking operations; and title operations in the United States. The company is involved in the acquisition and development of land primarily for residential purposes.
Finally, Cerus Corporation (NASDAQ:CERS), ended its last trade with 1.62% gain, and closed at $5.02.
Cerus Corporation, declared that its second quarter results will be released on Thursday, August 6, 2015 after the close of the stock market. The company will host a conference call and webcast at 4:15 PM ET that afternoon, during which administration will talk about the Company’s financial results and provide a general business overview and outlook.
Cerus Corporation operates as a biomedical products company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
